Japan Cancer Supportive Care Drugs Market Size & Outlook
Japan cancer supportive care drugs market, 2018-2030 (US$M)
Related Markets
Japan cancer supportive care drugs market highlights
- The Japan cancer supportive care drugs market generated a revenue of USD 557.2 million in 2023 and is expected to reach USD 529.3 million by 2030.
- The Japan market is expected to grow at a CAGR of -0.7% from 2024 to 2030.
- In terms of segment, antiemetics was the largest revenue generating therapeutic class in 2023.
- NSAIDs and Others is the most lucrative therapeutic class segment registering the fastest growth during the forecast period.
Cancer supportive care drugs market data book summary
| Market revenue in 2023 | USD 557.2 million |
| Market revenue in 2030 | USD 529.3 million |
| Growth rate | -0.7% (CAGR from 2023 to 2030) |
| Largest segment | Antiemetics |
| Fastest growing segment | NSAIDs and Others |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
| Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
Other key industry trends
- In terms of revenue, Japan accounted for 4.2% of the global cancer supportive care drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan cancer supportive care drugs market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 346.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Supportive Care Drugs Market Scope
Cancer Supportive Care Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan cancer supportive care drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Antiemetics was the largest segment with a revenue share of 25.68% in 2023. Horizon Databook has segmented the Japan cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
Cancer is the most common cause of death in Japan. Large geriatric population in the country is one of the major factors responsible for increase in the prevalence of cancer. Lung cancer is the leading cause of cancer-related deaths in Japan, followed by stomach and colorectal cancers. According to Globocan report, in 2020, around 1.03 million new cancer cases were reported in Japan, of which ~138,532 were lung cancer, and ~138,470 were stomach cancer cases.
According to Japan Society of Clinical Oncology, the recommendations for cancer supportive care drugs in Japan include non-opioids drugs such as NSAIDs & common analgesics for mild to moderate pain and opioid medications for severe pain. Factors such as structured healthcare recommendations for cancer care coupled with rising patient awareness are driving the market growth in Japan.
Reasons to subscribe to Japan cancer supportive care drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan cancer supportive care drugs market databook
-
Our clientele includes a mix of cancer supportive care drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan cancer supportive care drugs market , including forecasts for subscribers. This country databook contains high-level insights into Japan cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan cancer supportive care drugs market size, by therapeutic class, 2018-2030 (US$M)
Japan Cancer Supportive Care Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
